Related Experiment Video
Updated: Feb 12, 2026

Spatial and Temporal Analysis of Active ERK in the C. elegans Germline
Published on: November 29, 2016
Induction of MEK/ERK activity by AZD8055 confers acquired resistance in neuroblastoma
Dong-Qing Xu1, Hidemi Toyoda1, Lei Qi1
1Department of Pediatrics, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu, Mie, Japan.
Abstract:
Mammalian target of rapamycin (mTOR) complex (mTORC) is frequently activated in diverse cancers. Although dual mTORC1/2 inhibitors are currently under development to treat various malignancies, the emergence of drug resistance has proven to be a major complication. AZD8055 is a novel, potent ATP-competitive and specific inhibitor of mTOR kinase activity, which blocks both mTORC1 and mTORC2 activation. In this study, we acquired AZD8055-resistant neuroblastoma (NB) cell sublines by using prolonged stepwise escalation of AZD8055 exposure (4-12 weeks). Here we demonstrate that the AZD8055-resistant sublines (TGW-R and SMS-KAN-R) exhibited marked resistance to AZD8055 compared to the parent cells (TGW and SMS-KAN). The cell cycle G1/S transition was advanced in resistant cells. In addition, the resistance against AZD8055 correlated with over-activation of MEK/ERK signaling pathway. Furthermore, combination of AZD8055 and MEK inhibitor U0126 enhanced the growth inhibition of resistant cells significantly in vitro and in vivo. In conclusion, these data show that targeting mTOR kinase and MEK/ERK signaling simultaneously might help to overcome AZD8055 resistance in NB.
Insights
Acquiring resistance to the mTOR inhibitor AZD8055 in neuroblastoma cells was linked to MEK/ERK pathway activation. Combining AZD8055 with a MEK inhibitor effectively inhibited resistant neuroblastoma growth.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Mammalian target of rapamycin (mTOR) complex (mTORC) activation is common in cancers.
- Dual mTORC1/2 inhibitors show promise, but drug resistance is a significant challenge.
- AZD8055 is a specific mTOR kinase inhibitor blocking both mTORC1 and mTORC2.
Purpose of the Study:
- To investigate the mechanisms of AZD8055 resistance in neuroblastoma (NB).
- To evaluate combination therapy strategies to overcome AZD8055 resistance in NB.
Main Methods:
- Developed AZD8055-resistant neuroblastoma cell sublines (TGW-R, SMS-KAN-R) through prolonged drug exposure.
- Assessed resistance levels, cell cycle progression, and signaling pathway activation (MEK/ERK).
- Evaluated the efficacy of combined AZD8055 and MEK inhibitor (U0126) treatment in vitro and in vivo.
Main Results:
- Resistant NB cells (TGW-R, SMS-KAN-R) showed significantly higher resistance to AZD8055 compared to parent cells.
- Resistant cells exhibited an advanced cell cycle G1/S transition.
- AZD8055 resistance correlated with MEK/ERK signaling pathway over-activation.
- Combination therapy with AZD8055 and U0126 significantly enhanced growth inhibition of resistant cells.
Conclusions:
- MEK/ERK pathway over-activation is a key mechanism driving AZD8055 resistance in neuroblastoma.
- Simultaneous targeting of mTOR kinase and MEK/ERK signaling is a potential strategy to overcome AZD8055 resistance in NB.
More Related Videos
07:55Subcellular Fractionation for ERK Activation Upon Mitochondrial-derived Peptide Treatment
Published on: September 25, 2017
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
Related Concept Videos
Resistivity
Resistance
Induction
A...
Self-Inductance
Consider a circuit connected to an AC source. As the current varies with time, the magnetic flux through the circuit correspondingly changes. Faraday's law tells us that an emf would...
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...